Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)

Blood

Volumn 108, Issue 6, 2006, Pages 1965-1971

  Teachey, David T ^a,b   Obzut, Dana A ^a   Axsom, Kelly ^a   Choi, John K ^a   Goldsmith, Kelly C ^a   Hall, Junior ^a   Hulitt, Jessica ^a   Manno, Catherine S ^a   Maris, John M ^a   Rhodin, Nicholas ^a   Sullivan, Kathleen E ^a   Brown, Valerie I ^a   Grupp, Stephan A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPOTHESIS; LYMPHADENOPATHY; LYMPHOID TISSUE; LYMPHOPROLIFERATIVE DISEASE; MEDICAL ASSESSMENT; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN SIZE; SPLENOMEGALY; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33748681906     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-01-010124     Document Type: Article

References (38)

1. Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ. 2003;10:124-133.
2. Teachey DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. 2005;105:2443-2448.
3. Bleesing JJ, Straus SE, Fleisher TA. Autoimmune lymphoproliferative syndrome: a human disorder of abnormal lymphocyte survival. Pediatr Clin North Am. 2000;47:1291-1310.
4. Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat Rev. 1981;8:63-87.
5. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol. 2002;128:255-266.
6. Brown VI, Fang J, Alcorn K, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci U S A. 2003;100:15113-15118.
7. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med. 1999;130:591-601.
8. Wirtzfeld LA, Wu G, Bygrave M, et al. A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model. Cancer Res. 2005;65:6337-6345.
9. Bleesing JJ, Brown MR, Novicio C, et al. A composite picture of TcR alpha/beta(+) CD4(-)CD8(-) T cells (alpha/beta-DNTCs) in humans with autoimmune lymphoproliferative syndrome. Clin Immunol. 2002;104:21-30.
10. Rao VK, Dugan F, Dale JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol. 2005;129:534-538.
11. Jonsson CA, Erlandsson M, Svensson L, Molne J, Carlsten H. Mycophenolate mofetil ameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRLlpr/lpr mice. Cell Immunol. 1999;197:136-144.
12. Birck R, Newman M, Braun C, et al. 15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis. Nephrol Dial Transplant. 2006;21:58-63.
13. Teachey DT, Obzut DA, Cooperman J, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood. 2005;107:1149-1155.
14. Huang S, Shu L, Easton J, et al. Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem. 2004;279:36490-36496.
15. Bossu P, Singer GG, Andres P, Ettinger R, Marshak-Rothstein A, Abbas AK. Mature CD4+ T lymphocytes from MRL/lpr mice are resistant to receptor-mediated tolerance and apoptosis. J Immunol. 1993;151:7233-7239.
16. Bleesing JJ, Brown MR, Dale JK, et al. TcR-alpha/beta(+) CD4(-)CD8(-) T cells in humans with the autoimmune lymphoproliferative syndrome express a novel CD45 isoform that is analogous to murine B220 and represents a marker of altered O-glycan biosynthesis. Clin Immunol. 2001;100:314-324.
17. Fischer K, Voelkl S, Heymann J, et al. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8- double-negative regulatory T cells. Blood. 2005;105:2828-2835.
18. Ogata Y, Kimura M, Shimada K, et al. Distinctive expression of lprcg in the heterozygous state on different genetic backgrounds. Cell Immunol. 1993;148:91-102.
19. Van Bruggen MC, Walgreen B, Rijke TP, Berden JH. Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol. 1998;9:1407-1415.
20. Peralba JM, DeGraffenried L, Friedrichs W, et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res. 2003;9:2887-2892.
21. Downward J. How Bad phosphorylation is good for survival. Nat Cell Biol. 1999;1:E33-E35.
22. Hui L, Rodrik V, Pielak RM, Knirr S, Zheng Y, Foster DA. mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. J Biol Chem. 2005;280:35829-35835.
23. Drosos AA. Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy. Drugs. 2002;62:891-907.
24. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int. 2001;59:3-16.
25. Schreiber SL. Chemistry and biology of immunophilins and their immunosupressive ligands. Science. 1991;251:283-287.
26. Majewski M, Korecka M, Kossev P, et al. The immunosupressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A. 2000;97:4285-4290.
27. Calne RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting [letter]. Lancet. 1989;2:227.
28. Ettenger RB, Grimm EM. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis. 2001;38:S22-S28.
29. Ucar B, Akgun N, Aydogdu SD, Kirel B, Idem S. Treatment of refractory Evans' syndrome with cyclosporine and prednisone. Pediatr Int. 1999;41:104-107.
30. Rackoff WR, Manno CS. Treatment of refractory Evans syndrome with alternate-day cyclosporine and prednisone. Am J Pediatr Hematol Oncol. 1994;16:156-159.
31. Izeradjene K, Quemeneur L, Michallet MC, Bonnefoy-Berard N, Revillard JP. Mycophenolate mofetil interferes with interferon gamma production in T-cell activation models. Transplant Proc. 2001;33:2110-2111.
32. Nogueras F, Espinosa MD, Mansilla A, Torres JT, Cabrera MA, Martin-Vivaldi R. Mycophenolate mofetil-induced neutropenia in liver transplantation. Transplant Proc. 2005;37:1509-1511.
33. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1998;65:1450-1454.
34. Kim JM, Fang J, Rheingold S, et al. Cytoplasmic micro heavy chain confers sensitivity to dexamethasone-induced apoptosis in early B-lineage acute lymphoblastic leukemia. Cancer Res. 2002;62:4212-4216.
35. Purton JF, Monk JA, Liddicoat DR, et al. Expression of the glucocorticoid receptor from the 1A promoter correlates with T lymphocyte sensitivity to glucocorticoid-induced cell death. J Immunol. 2004;173:3816-3824.
36. Oliveira VD, Zankl H, Rath T. Mutagenic and cytotoxic effects of immunosuppressive drugs on human lymphocyte cultures. Exp Clin Transplant. 2004;2:273-279.
37. van der Werff Ten Bosch J, Schotte P, Ferster A, et al. Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations. Br J Haematol. 2002;117:176-188.
38. Singer GG, Carrera AC, Marshak-Rothstein A, Martinez C, Abbas AK. Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr Opin Immunol. 1994;6:913-920.